🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

FDA approves CSL's Andembry for preventing HAE attacks firstwordpharma.com/story/5973298

UPDATE: Liking what it sees, Lilly to buy base editing partner Verve for $1.3B $LLY $VERV firstwordpharma.com/story/5973307

Immuneering touts strong survival in pancreatic cancer trial $IMRX firstwordpharma.com/story/5973394

FDA's new speedy review programme will be open only to US drugmakers firstwordpharma.com/story/5973461

Mineralys builds case for blood pressure drug – this time in CKD $MLYS firstwordpharma.com/story/5973559

Neuropsychiatry startup Draig launches with $140M series A firstwordpharma.com/story/5973663

FDA approves Gilead's twice-yearly HIV prevention shot $GILD firstwordpharma.com/story/5973839

Scholar Rock says its drug helps Zepbound users retain more muscle $SRRK $LLY firstwordpharma.com/story/5973730

BioNTech halts cell therapy manufacturing at Maryland site, lays off dozens $BNTX firstwordpharma.com/story/5973847

After upsized IPO, Caris Life Sciences shoots to even greater heights in trading debut $CAI firstwordpharma.com/story/5973910

Incyte's Monjuvi scores FDA win in follicular lymphoma $INCY firstwordpharma.com/story/5973931

Prothena slashes workforce by 63% to slow its cash burn $PRTA firstwordpharma.com/story/5973962

Regeneron backs Actio's $66M rare disease clinical push $REGN firstwordpharma.com/story/5974326

NICE reaffirms negative stance on Alzheimer's therapies Kisunla, Leqembi $LLY $BIIB firstwordpharma.com/story/5974353

FDA to tighten up on use of American patients' biological material in "hostile countries" firstwordpharma.com/story/5974345

Adding GLP-2 to the mix, Zealand's dapiglutide hits over 11% weight loss $ZEAL firstwordpharma.com/story/5974512

Sanofi, Regeneron's Dupixent scores eighth FDA nod, this time for bullous pemphigoid $SNY $REGN firstwordpharma.com/story/5974921

ACIP's new agenda: HPV jabs are out, thimerosal-containing flu vaccines are in firstwordpharma.com/story/5974593

Madrigal's Rezdiffra nears EU approval for MASH after positive panel review $MDGL firstwordpharma.com/story/5974932

FDA gene therapy leaders sidelined amid broader agency overhaul firstwordpharma.com/story/5974963